NCT04640311View on ClinicalTrials.gov

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

May 18, 2021

Study Completion Date

May 18, 2021

Conditions
Anaemia
Interventions
DRUG

Daprodustat

Daprodustat will be available as oral tablets.

Trial Locations (4)

66212

GSK Investigational Site, Overland Park

78744

GSK Investigational Site, Austin

89113

GSK Investigational Site, Las Vegas

92801

GSK Investigational Site, Anaheim

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04640311 - Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants | Biotech Hunter | Biotech Hunter